1330037-21-2
Chemical Structure
N-Isovalerylglycine-d9
- CAS No.: 1330037-21-2
- Formula:C7H4D9NO3
- Molecular Weight:168.24
IUPAC Name: (3-(methyl-d3)butanoyl-2,2,3,4,4,4-d6)glycine
InChIKey: ZRQXMKMBBMNNQC-APXHDBETSA-N
SMILES: O=C(O)CNC(C([2H])([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O
Biological Activity: N-Isovalerylglycine-d9 is the deuterium labeled N-Isovaleroylglycine (HY-W015464). N-Isovaleroylglycine is a peptidylglycine α-amidating monooxygenase (PAM) inhibitor with a Ki value of 2.0 mM against human hsPAM. N-Isovaleroylglycine undergoes oxidative cleavage by purified rat PAM to produce fatty acid amide and glyoxylic acid. N-Isovaleroylglycine exerts competitive inhibition by binding to hsPAM, blocking the amidation of dansyl-Tyr-Val-Gly. N-Isovaleroylglycine exhibits lowered urinary abundance in MRSA-infected mice, which qualifies it as a non-invasive biomarker. N-Isovaleroylglycine can be used in studies related to Staphylococcus aureus pneumonia and diabetic foot[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-Isovalerylglycine-d9 | 99.0% | N-Isovalerylglycine-d9 is the deuterium labeled N-Isovaleroylglycine (HY-W015464). N-Isovaleroylglycine is a peptidylglycine α-amidating monooxygenase (PAM) inhibitor with a Ki value of 2.0 mM against human hsPAM. N-Isovaleroylglycine undergoes oxidative cleavage by purified rat PAM to produce fatty acid amide and glyoxylic acid. N-Isovaleroylglycine exerts competitive inhibition by binding to hsPAM, blocking the amidation of dansyl-Tyr-Val-Gly. N-Isovaleroylglycine exhibits lowered urinary abundance in MRSA-infected mice, which qualifies it as a non-invasive biomarker. N-Isovaleroylglycine can be used in studies related to Staphylococcus aureus pneumonia and diabetic foot. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Isovaleroylglycine (Standard) | ≥98% | N-Isovaleroylglycine (Standard) is the analytical standard of N-Isovaleroylglycine (HY-W015464). This product is intended for research and analytical applications. N-Isovaleroylglycine is a peptidylglycine α-amidating monooxygenase (PAM) inhibitor with a Ki value of 2.0 mM against human hsPAM. N-Isovaleroylglycine undergoes oxidative cleavage by purified rat PAM to produce fatty acid amide and glyoxylic acid. N-Isovaleroylglycine exerts competitive inhibition by binding to hsPAM, blocking the amidation of dansyl-Tyr-Val-Gly. N-Isovaleroylglycine exhibits lowered urinary abundance in MRSA-infected mice, which qualifies it as a non-invasive biomarker. N-Isovaleroylglycine can be used in studies related to Staphylococcus aureus pneumonia and diabetic foot. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Isovaleroylglycine-13C2,15N | N-Isovaleroylglycine-13C2,15N is the 13C- and 15N-labeled N-Isovaleroylglycine (HY-W015464). N-Isovaleroylglycine is an acyl glycine and could be used as a biomarker for the predispositon for weight gain and obesity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Isovaleroylglycine | 99.86% | N-Isovaleroylglycine is a peptidylglycine α-amidating monooxygenase (PAM) inhibitor with a Ki value of 2.0 mM against human hsPAM. N-Isovaleroylglycine undergoes oxidative cleavage by purified rat PAM to produce fatty acid amide and glyoxylic acid. N-Isovaleroylglycine exerts competitive inhibition by binding to hsPAM, blocking the amidation of dansyl-Tyr-Val-Gly. N-Isovaleroylglycine exhibits lowered urinary abundance in MRSA-infected mice, which qualifies it as a non-invasive biomarker. N-Isovaleroylglycine can be used in studies related to Staphylococcus aureus pneumonia and diabetic foot. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Slupsky CM, et al. Streptococcus pneumoniae and Staphylococcus aureus pneumonia induce distinct metabolic responses. Journal of proteome research. 2009 Jun;8(6):3029-36. [Content Brief]
- [2]. Merkler KA, et al. A Pathway for the Biosynthesis of Fatty Acid Amides. In: Honn KV, Marnett LJ, Nigam S, Dennis EA, eds. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 4. Advances in Experimental Medicine and Biology, vol 469. Springer; 1999.
- [3]. Lian F, et al. Distinct urine and plasma metabolic signatures in diabetic foot: early diagnostic biomarkers and predictive modeling. BMC endocrine disorders. 2025 Dec 29;25(1):285. [Content Brief]
